These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1017 related articles for article (PubMed ID: 32283108)
1. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108 [TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223 [TBL] [Abstract][Full Text] [Related]
3. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products. Khan A; Khan M; Saleem S; Babar Z; Ali A; Khan AA; Sardar Z; Hamayun F; Ali SS; Wei DQ Interdiscip Sci; 2020 Sep; 12(3):335-348. PubMed ID: 32617855 [TBL] [Abstract][Full Text] [Related]
4. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Yin W; Mao C; Luan X; Shen DD; Shen Q; Su H; Wang X; Zhou F; Zhao W; Gao M; Chang S; Xie YC; Tian G; Jiang HW; Tao SC; Shen J; Jiang Y; Jiang H; Xu Y; Zhang S; Zhang Y; Xu HE Science; 2020 Jun; 368(6498):1499-1504. PubMed ID: 32358203 [TBL] [Abstract][Full Text] [Related]
5. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase. Zhang L; Zhou R J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159 [TBL] [Abstract][Full Text] [Related]
7. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225 [TBL] [Abstract][Full Text] [Related]
8. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase. Wang Q; Wu J; Wang H; Gao Y; Liu Q; Mu A; Ji W; Yan L; Zhu Y; Zhu C; Fang X; Yang X; Huang Y; Gao H; Liu F; Ge J; Sun Q; Yang X; Xu W; Liu Z; Yang H; Lou Z; Jiang B; Guddat LW; Gong P; Rao Z Cell; 2020 Jul; 182(2):417-428.e13. PubMed ID: 32526208 [TBL] [Abstract][Full Text] [Related]
9. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628 [TBL] [Abstract][Full Text] [Related]
10. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326 [TBL] [Abstract][Full Text] [Related]
11. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR mBio; 2018 Mar; 9(2):. PubMed ID: 29511076 [TBL] [Abstract][Full Text] [Related]
12. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Robson F; Khan KS; Le TK; Paris C; Demirbag S; Barfuss P; Rocchi P; Ng WL Mol Cell; 2020 Sep; 79(5):710-727. PubMed ID: 32853546 [TBL] [Abstract][Full Text] [Related]
13. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278 [TBL] [Abstract][Full Text] [Related]
14. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir. Banerjee A; Kanwar M; Maiti S Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419 [TBL] [Abstract][Full Text] [Related]
15. Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV. Singh PK; Pathania S; Rawal RK SAR QSAR Environ Res; 2020 Nov; 31(11):857-867. PubMed ID: 33100032 [TBL] [Abstract][Full Text] [Related]
16. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19. Chien M; Anderson TK; Jockusch S; Tao C; Li X; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J J Proteome Res; 2020 Nov; 19(11):4690-4697. PubMed ID: 32692185 [TBL] [Abstract][Full Text] [Related]
18. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Jockusch S; Tao C; Li X; Anderson TK; Chien M; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J Antiviral Res; 2020 Aug; 180():104857. PubMed ID: 32562705 [TBL] [Abstract][Full Text] [Related]
19. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Gao Y; Yan L; Huang Y; Liu F; Zhao Y; Cao L; Wang T; Sun Q; Ming Z; Zhang L; Ge J; Zheng L; Zhang Y; Wang H; Zhu Y; Zhu C; Hu T; Hua T; Zhang B; Yang X; Li J; Yang H; Liu Z; Xu W; Guddat LW; Wang Q; Lou Z; Rao Z Science; 2020 May; 368(6492):779-782. PubMed ID: 32277040 [TBL] [Abstract][Full Text] [Related]
20. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. Martin R; Li J; Parvangada A; Perry J; Cihlar T; Mo H; Porter D; Svarovskaia E Antiviral Res; 2021 Apr; 188():105033. PubMed ID: 33549572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]